- Dr. Orly Avni, Ezh2 regulates early stages of T helper cell differentiation
- Prof. Arie Admon, Analysis of the HLA peptidome for development of personalized cancer immunotherapy
- Prof. Ronen Alon, Nuclear Checkpoints for Melanoma and Breast Cancer Lung Metastasis
-
Prof. Roni Apte, Are we mature enough to apply anti-IL-1beta therapy in cancer patients?
- Dr. Amiram Ariel, IFNß is a Novel Effector Cytokine in Resolving Inflammation
- Prof. Michal Baniyash, Myeloid Derived Suppressor Cells as Plastic Sensors and Outcome Orchestrators During Chronic Inflammation
- Dr. Adi Barzel, Engineering B cells as an evolving drug to fight HIV
- Dr. Shai Bel, Inflammation and Host-Pathogen Interaction section or the Microbiome & Immunity section?
- Prof. Yinon Ben Neriah, Targeting transcriptional addiction in leukemia
- Prof. Adit Ben-Baruch, Notch-mediated processes promoting inflammation-driven mechanisms in breast cancer progression
- Dr. Michael Berger, Mitochondrial Matrix-Compartment-Energetics Limits Hypoxia Tolerance During CD8 T cell Priming
- Prof. Yehudit Bergman, Epigenetic programming of intestinal inflammation – a role for the microbiota
- Dr. Yaron Carmi, A distinct subset of Th1 cells express the high-affinity Fcγ receptor and exert antibody-mediated cytotoxic activity in solid tumors
- Dr. Tomer Cooks, Mutant p53 controls the tumor microenvironment via extracellular vesicles: interactions with immune cells and microbiome
- Dr. Ronnie Dahan, The Role of Fc Receptors in the Therapeutic Anti-Tumor Activity of Checkpoint Antibodies
-
Dr. Moshe Elkabets, CD8 T cells enhance the anti-tumor efficacy of Trametinib in head and neck cancer
- Prof. Neta Erez, Stromal dynamic plasticity drives an inflammatory microenvironment in breast cancer metastasis
-
Prof. Zvi Fridlender, Neutrophils as modulators of the immune tumor microenvironment
- Dr. Roi Gazit, Immune Stimulation for Hematopoietic Stem Cells
- Prof. Tami Geiger, Proteomics of Melanoma Response to Immunotherapy Reveals Dependence on Mitochondrial Function
- Dr. Zvika Granot, Hallmarks of Neutrophil Anti Tumor Cytotoxicity
- Dr. Ayal Hendel, CRISPR Gene Correction: A Potential New Class of Medicines for Primary Immunodeficiency Diseases
- Prof. Uri Hershberg, A Tissue Atlas of Human B-Cell Receptor clones tracks their inter and intra clonal evolution
- Prof. Shai Izraeli, Targeting signaling for cancer treatment – opportunities and challenges
- Prof. Steffen Jung, Keep calm and IL-10, a story of gut and brain macrophages
- Prof. Nati Karin, Chemokines in the interface between cancer and autoimmunity
- Prof. Valery Krizhanovsky, Impaired Immune Surveillance Accelerates Accumulation of Senescent Cells and Aging
- Prof. Sarit Larisch, ARTS and ARTS mimetics promote cancer cell killing by degrading anti-apoptotic proteins
- Prof. Doron Melamed, B cell homeostasis under control of microRNAs
- Prof. Dror Mevorach, Synergism between human apoptotic cell infusion and human chimeric antigen receptor (CAR)-T therapy in fighting solid human tumor in SCID Bg mice
- Prof. Alon Monsenego, Aging promotes reorganization of the CD4 T-cell landscape toward extreme phenotypes implicated in age-related diseases
- Dr. Dinorah Morvinski, Cell state plasticity and the generation of intra-tumor heterogeneity in glioblastoma
- Prof. Ariel Munitz, Type 2 Immunity in Inflammation and Cancer
- Prof. Uri Nir, Fer and FerT sustain the metabolic plasticity of metastatic non-small cell lung cancer cells
- Prof. Gabriel Nussbaum, Exploring the link between the oral microbe Porphyromonas gingivalis and pancreatic cancer
- Prof. Moshe Oren, p53 deregulation in cancer: cell-autonomous and non-autonomous implications
- Dr. Niv Papo, Engineering Affinity, Specificity and Stability in Protein Therapeutics
- Prof. Eli Pikarsky, Pro and Anti tumorigenic functions of tertiary lymphoid structures
- Dr. Jacob Rachmilevitz, Macrophage-assisted DNA damage response
- Prof. Michal Rahat, Necroptosis induced by anti-EMMPRIN antibody and complement shifts macrophage polarization.
- Prof. Asya Rolls, Neuronal regulation of anti-tumor immunity
- Dr. Noga Ron-Harel, The metabolic liability of T cell activation
- Prof. Ronit Satchi-Fainaro, Ibrutinib-disabled immunosuppressive microenvironment sensitizes melanoma to PD-1/OX40 immune checkpoint modulators following immunization with nano-vaccines
- Prof. Ruth Scherz-Shouval, Cancer-associated fibroblast heterogeneity in breast cancer
- Dr. Mark Schvartzman, The Role of Nanoscale Mechanosensing and Spatial Receptor Distribution in the Activation of Natural Killer Cells
- Prof. Michal Schwartz, The potential of immune checkpoint blockade for fighting against Alzheimer`s disease
- Prof. Idit Shachar, The molecular mechanisms regulating the cross talk between CLL cells and their microenvironment
- Dr. Eilon Sherman, Resolving mechanisms of T cell activation at the single molecule level
- Dr. Liran Shlush, Predicting AML risk in healthy individuals
- Prof. Hermona Soreq, Sex-related perturbations in schizophrenia and bipolar disorder brains reflect microRNA-mediated cholinergic/neurokine interactions
- Dr. Itay Tirosh, Dissecting the glioma ecosystem by single cell RNA-seq
- Dr. Debbie Yablonski, Bridging the Gap: Modulatory roles of the Grb2-family adaptor, Gads, in cellular and allergic immune responses
-
Prof. Yossi Yarden, Targeting tumours' addictions using antibodies